Literature DB >> 9893762

The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions.

P J Roderick1, G Ferris, T G Feest.   

Abstract

We assessed the level of provision of renal replacement therapy for adults in England and Wales. All autonomous main renal units in England (n = 52) and Wales (n = 5) were surveyed in 1996. Data for England were compared to the 1993 National Renal Review. The acceptance rate in England 1995 was 82 (80-85) per million population (p.m.p.) compared with 67 (65-70) p.m.p. in 1991-2. The rate in 1995 in Wales was 109 (98-122) p.m.p. The prevalence rate in England was 476 p.m.p. at end-1995 compared to 393 p.m.p. in 1993, in Wales it was 487 p.m.p. The number of main renal units in England did not rise between 1993 and 1995; capacity was increased by use of more treatment shifts and temporary haemodialysis stations, and by opening more satellite units. The main growth was in hospital haemodialysis. There was an uneven geographical distribution of services. Patients accepted were older with more comorbidity. The use of better-quality processes of dialysis increased. The steady-state position for RRT will not be reached for over a decade. Health authorities will face continued pressure to fund increases in quantity and quality improvements. A stronger evidence base of the effectiveness of therapies, and a national registry to monitor the equity and cost-effectiveness of services are needed.

Entities:  

Mesh:

Year:  1998        PMID: 9893762     DOI: 10.1093/qjmed/91.8.581

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  2 in total

1.  Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.

Authors:  Stephen J Walters; Malcolm Whitfield; Ronald L Akehurst; James B Chilcott
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  The effect of gender, age, and geographical location on the incidence and prevalence of renal replacement therapy in Wales.

Authors:  Hugo C van Woerden; Jane Wilkinson; Martin Heaven; Jason Merrifield
Journal:  BMC Nephrol       Date:  2007-01-11       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.